Overall verdict
Neutral
5.2/10
1-year performance
+74.80%
Score breakdown
Up 74.8% over 1 year, 95% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Valuation 0.1/10.
28 analysts, target -0.1% vs the price.
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries.
It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nse
India
CEO
Kiran Divi
Founded
1990
Employees
19 292
Revenue / employee
5.5M INR
Next earnings
February 6, 2027 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
11824.00 INR
52-week low
5647.50 INR
1-year performance
74.80%
Rising
Year-to-date performance
79.51%
Rising
Drawdown
-2.87%
Near its high
Position in the 52-week range
95% of range
Gross margin 48.0%, net margin 27.6%, ROIC 20.1%, ROE 20.1%.
Net margin
27.59%
Exceptional
Sector 3.88%|S&P 13.40%
Gross margin
47.96%
High
Return on equity (ROE)
20.13%
Exceptional
Sector 3.46%|S&P 17.06%
Return on invested capital (ROIC)
20.13%
Exceptional
Free cash flow margin (FCF)
-10.84%
Negative
Profit-to-cash conversion (FCF conversion)
-0.39x
Low
Margin stability
3.4 pts
Steady
Revenue to net income
Growth
5.9/10Revenue up 35.4% over 1 year, 8.9% a year over 5, EPS 5.3% a year over 5.
Revenue (trailing 12 months)
119Md INR
Revenue growth (1y)
35.40%
Hyper-growth
Revenue growth (3y)
36.12%
Solid
EPS growth (1y)
17.21%
Solid
EPS CAGR (5y)
5.29%
Low
EPS revisions (3 months)
20.95%
Sharply revised up
Valuation
0.1/10P/E 90.7x, forward P/E 76.7x, EV/EBITDA 65.9x, PEG 17.13. The multiple sits in the 100th percentile of its own 5-year history.
P/E (TTM)
90.7x
Expensive
Sector 46.3x|S&P 23.6x
Forward P/E
76.7x
Very expensive
EV / EBITDA
65.9x
Very expensive
Sector 22.4x|S&P 15.5x
PEG
17.13
Very expensive
Sector 0.88|S&P 0.91
P/E vs its own 5-year history
among the 1% highest valuations
At its historical high
Market cap
3.0T INR
Financial strength
10.0/10Cash covers 37266.7% of the debt, net debt/EBITDA -1.0x.
Net debt / EBITDA
-1.0x
Net cash
Gearing (net debt / equity)
-12.39%
Net cash
Cash
21.8Md INR
Cash / market cap
0.73%
Stretched
Cash / total debt
37266.67%
Net cash
Interest coverage
133.3x
Very solid
Net debt
-21.7Md INR
Equity
175Md INR
Closed daily candles, 2 years
Last close on November 11, 2026: 11,367.00 INR
- MM209,784.10
- MM509,539.04
- MM2007,479.71
- RSI 1479.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.92%
200-day average slope, 3 months
+13.85%
50-day average slope, 1 month
+5.56%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.35 % per day
Volatility change
+51.82%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 149.72 (13) | 148.42 (23) | 137 634 (23) | 54 539 (23) | 39 522 (15) |
Amounts in millions of INR, EPS in INR per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 104 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.7 | 8.2 | 68.4Md USD | — | — | 70.5 % | — | -1.7x | — | 62.1 % | ||
| 2 | IQV | 7.3 | 6.9 | 45.2Md USD | 33.4x | 8.1 % | 8.0 % | 6.8 % | 4.1x | 4.6 % | 28.0 % | ||
| 3 | A207940 | 7.1 | 7.0 | 52.5Md USD | 39.7x | 41.1 % | -10.2 % | — | -0.2x | — | -24.4 % | ||
| 4 | A | 6.5 | 6.0 | 49.9Md USD | 34.8x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.5 % | 20.4 % | ||
| 5 | DHR | 6.5 | 6.4 | 166Md USD | 38.5x | 16.7 % | 8.3 % | 5.9 % | 2.0x | 3.5 % | 11.5 % | ||
| 6 | TMO | 6.2 | 5.5 | 266Md USD | 37.9x | 14.9 % | 9.1 % | 8.0 % | 2.8x | 2.9 % | 24.6 % | ||
| 7 | LONN | 5.6 | 4.7 | 54.1Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.5 % | 22.7 % | ||
| 8 | DIVISLAB | 5.2 | 4.9 | 32.0Md USD | 90.7x | 27.6 % | 35.4 % | 20.1 % | -1.0x | -0.4 % | 74.8 % | ||
| 9 | WAT | 4.3 | 1.7 | 46.3Md USD | 202.3x | 1.8 % | 120.9 % | 0.8 % | 0.8x | 0.6 % | 23.9 % |
